Terumo Corporation Acquires OrganOx for $1.5 Billion

Symeres Acquires Organix Inc.

April 26, 2022

Biotechnology

Symeres, a European drug discovery CRO/CDMO backed by Keensight Capital, has acquired Organix Inc., a Woburn, Massachusetts-based organic chemistry services provider specializing in lipids. The deal gives Symeres a strategic US foothold and expands its capabilities into the fast-growing lipids market supporting mRNA therapeutics and vaccines; Organix generates over $10 million in revenue and has roughly 45 employees.

Quanterix Completes Acquisition of Akoya Biosciences

July 8, 2025

Healthcare Services

Quanterix completed its previously announced acquisition of Akoya Biosciences under the amended merger agreement, issuing about 7.8 million shares and paying about $20 million in cash in the aggregate to Akoya holders. The companies positioned the deal as creating an integrated platform for measuring biomarkers across the blood and tissue continuum and expanding addressable markets.

Terumo Corporation Acquires Health Outcomes Sciences, Inc.

February 24, 2021

Cloud & SaaS

Terumo Corporation has entered a definitive agreement to acquire all assets of Health Outcomes Sciences, Inc., including the ePRISM predictive analytics and clinical decision support platform. The acquisition will expand Terumo's digital healthcare capabilities by integrating ePRISM into Terumo Business Edge to deliver patient-specific predictive insights at the point of care and improve outcomes while lowering costs.

Zylox-Tonbridge to Acquire Optimed Medizinische Instrumente GmbH

January 16, 2026

Medical Devices

Zylox-Tonbridge entered into a definitive agreement to acquire Germany-based medical device company Optimed Medizinische Instrumente GmbH in multiple steps, with an option to acquire its entire equity interest from existing shareholders. The deal is intended to create an integrated global commercialization platform for Optimed’s minimally invasive vascular and endourology products and to deliver manufacturing and operational synergies between Germany and China.

BioStem Technologies Acquires BioTissue's Surgical and Wound Care Business

January 22, 2026

Medical Devices

BioStem Technologies (OTC: BSEM) has acquired the surgical and wound care business of BioTissue Holdings, Inc. for approximately $15 million upfront, with up to $25 million of contingent milestone and royalty payments. The deal includes the Neox and Clarix product lines, a nationwide commercial sales organization and assigned GPO contracts, expanding BioStem's access into hospital inpatient and outpatient wound-care markets and adding assets that generated roughly $29 million in 2025.

WuXi AppTec Completes Acquisition of OXGENE

March 2, 2021

Biotechnology

WuXi AppTec, via its cell and gene therapy unit WuXi Advanced Therapies (WuXi ATU), completed the acquisition of Oxford-based OXGENE on March 2, 2021. The purchase brings OXGENE's gene-therapy discovery and viral-vector manufacturing technologies into WuXi ATU, expanding its capabilities and establishing its first European facility to better serve global cell and gene therapy customers.